| scholarly article | Q13442814 |
| P2093 | author name string | Qinghua Wang | |
| Juan Zheng | |||
| Ali Fathi | |||
| Junfeng Li | |||
| Harry K Lau | |||
| Susanne Wang | |||
| P2860 | cites work | Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor | Q24318252 |
| GLP-1 and cardioprotection: from bench to bedside | Q27024984 | ||
| Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain | Q28256443 | ||
| DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells | Q28257599 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist | Q28475510 | ||
| Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms | Q28535415 | ||
| Cardiac function in mice lacking the glucagon-like peptide-1 receptor | Q28586718 | ||
| Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency | Q28740948 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles | Q30411123 | ||
| GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle | Q30418716 | ||
| Role of smooth muscle cells in the initiation and early progression of atherosclerosis | Q30438867 | ||
| Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure | Q30478488 | ||
| Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice | Q33750640 | ||
| Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells | Q33898060 | ||
| The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. | Q33932817 | ||
| Bariatric surgery and long-term cardiovascular events. | Q34030064 | ||
| GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure | Q34336097 | ||
| The biology of incretin hormones | Q34499706 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. | Q34653078 | ||
| Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 | ||
| Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care | Q34984643 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients | Q35654597 | ||
| GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice | Q35769544 | ||
| Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice | Q47403266 | ||
| Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure | Q48408264 | ||
| Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. | Q50509855 | ||
| Supplemental hydrogen sulphide protects transplant kidney function and prolongs recipient survival after prolonged cold ischaemia-reperfusion injury by mitigating renal graft apoptosis and inflammation. | Q50896244 | ||
| Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. | Q51307758 | ||
| A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. | Q51362571 | ||
| GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. | Q51381163 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. | Q54454763 | ||
| Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 | ||
| Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation | Q60312974 | ||
| Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. | Q64998688 | ||
| Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides | Q70942068 | ||
| Regulation and Differential Expression of Neutral Endopeptidase 24.11 in Human Endothelial Cells | Q71959170 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride | Q80825411 | ||
| Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart | Q81538720 | ||
| Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury | Q83151449 | ||
| Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor | Q84187312 | ||
| [Effects of glucagon-like peptide 1(9-36) on endothelial nitric oxide synthase in human umbilical vein endothelial cells] | Q85912555 | ||
| Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice | Q86916012 | ||
| Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis | Q35769898 | ||
| Cell-surface peptidases | Q35818705 | ||
| Circulation and degradation of GIP and GLP-1. | Q36012469 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial | Q36063048 | ||
| Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice | Q36331561 | ||
| Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor | Q36471233 | ||
| Cardiovascular biology of the incretin system | Q36484283 | ||
| Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. | Q36836773 | ||
| Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes | Q36850966 | ||
| Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus | Q37065219 | ||
| Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies | Q37172727 | ||
| Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis | Q37209666 | ||
| Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. | Q37635255 | ||
| Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. | Q37687612 | ||
| Minireview: update on incretin biology: focus on glucagon-like peptide-1. | Q37715583 | ||
| The structure and function of the glucagon-like peptide-1 receptor and its ligands | Q37939244 | ||
| Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1 | Q38177382 | ||
| GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery? | Q38307449 | ||
| The regulation of function, growth and survival of GLP-1-producing L-cells | Q38659256 | ||
| Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis | Q38673335 | ||
| 7. Approaches to Glycemic Treatment | Q38676991 | ||
| Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study | Q38919256 | ||
| GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. | Q39030156 | ||
| Evidence for paracrine/autocrine regulation of GLP-1-producing cells | Q39103643 | ||
| Cardioprotective effects of exenatide against oxidative stress-induced injury | Q39104148 | ||
| Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells | Q39234083 | ||
| Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells | Q39277813 | ||
| Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells | Q39304557 | ||
| Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice | Q39309484 | ||
| Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes | Q39600857 | ||
| The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells | Q39774031 | ||
| Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. | Q39778606 | ||
| Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. | Q39990285 | ||
| Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells | Q40592531 | ||
| Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury | Q40947688 | ||
| Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats | Q41809232 | ||
| Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model | Q41826601 | ||
| GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 | ||
| Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis | Q42022343 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway | Q42594418 | ||
| Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes | Q42824310 | ||
| A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells | Q42996825 | ||
| Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. | Q43071459 | ||
| Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. | Q43155141 | ||
| Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue | Q43237616 | ||
| Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation | Q43763511 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice | Q44145661 | ||
| In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes | Q44317184 | ||
| Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury | Q44321259 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study | Q45232445 | ||
| Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. | Q45930780 | ||
| Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. | Q45954775 | ||
| LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells | Q46353648 | ||
| Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes | Q46381951 | ||
| Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes | Q46415493 | ||
| GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. | Q46426083 | ||
| Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy | Q46604606 | ||
| Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. | Q46605092 | ||
| Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials | Q46637270 | ||
| GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide | Q46637836 | ||
| Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 | ||
| Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years | Q46870991 | ||
| The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes | Q46872862 | ||
| GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice | Q47377801 | ||
| P304 | page(s) | 15 | |
| P577 | publication date | 2017-01-30 | |
| P1433 | published in | Frontiers in Physiology | Q2434141 |
| P1476 | title | Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies | |
| P478 | volume | 8 |
| Q47899237 | Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling |
| Q60044940 | GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data |
| Q90737641 | Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes |
| Q33679277 | Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice |
| Q47180841 | Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. |
Search more.